Relapsed Pancreatoblastoma in Children: The Quest for Cure in This Rare Entity

Pancreatoblastoma constitutes the most common malignant pancreatic tumor in children. Pancreatoblastomas are rare and data to generate evidence-based management guidelines are limited. A literature review and pooled data analysis of cases 18 years old or younger with relapsed pancreatoblastoma (RP) was performed to describe their prognosis and management. The 2-year overall survival post-relapse (OS-pr) for patients with RP (n=15) was 54.4% (95% CI: 32.5%-71.6%). On the basis of surgery at relapse, the 2-year OS-pr was 85.7% (95% CI: 59.8%-96.1%) for cases who underwent surgery (n=9) versus 16.7% (95% CI: 1.1%-44.9%) for nonsurgical cases (n=6); P=0.003. This study shows that patients with RP can be salvaged and supports pursuing treatment with curative intent, including maximal safe resection where feasible.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Hematology/Oncology
Published
2025-09-25
DOI
https://doi.org/10.1097/mph.0000000000003115
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Relapsed Pancreatoblastoma in Children: The Quest for Cure in This Rare Entity

Nigel Heaton, Fernando Carceller, Stergios Zacharoulis, Erika Pace et al.
Journal of Pediatric Hematology/Oncology
Pancreatic and Hepatic Oncology Research
article

Relapsed Pancreatoblastoma in Children: The Quest for Cure in This Rare Entity

Nigel Heaton, Fernando Carceller, Stergios Zacharoulis, Erika Pace, Maesha Deheragoda, Carlos Echecopar
article en

Abstract

Pancreatoblastoma constitutes the most common malignant pancreatic tumor in children. Pancreatoblastomas are rare and data to generate evidence-based management guidelines are limited. A literature review and pooled data analysis of cases 18 years old or younger with relapsed pancreatoblastoma (RP) was performed to describe their prognosis and management. The 2-year overall survival post-relapse (OS-pr) for patients with RP (n=15) was 54.4% (95% CI: 32.5%-71.6%). On the basis of surgery at relapse, the 2-year OS-pr was 85.7% (95% CI: 59.8%-96.1%) for cases who underwent surgery (n=9) versus 16.7% (95% CI: 1.1%-44.9%) for nonsurgical cases (n=6); P=0.003. This study shows that patients with RP can be salvaged and supports pursuing treatment with curative intent, including maximal safe resection where feasible.

Journal of Pediatric Hematology/OncologyVol. 47(8)
Royal Marsden NHS Foundation Trust (GB), Institute of Cancer Research (GB), Columbia University Irving Medical Center (US), Hospital Universitario La Paz (ES), King's College Hospital (GB)
Openalex Percentile: Top 58%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.